An inhaled formulation of the decades-old mast cell stabilizer cromolyn sodium is heading back into Phase III Alzheimer's disease testing, this time with an APOE4-stratified trial designed around an exploratory signal from an earlier late-stage study. Massachusetts-based PhenoNet said the US FDA cleared its IND for PHENOGENE-1A on August 10, allowing a 648-patient Phase III trial to begin.
Cromolyn sodium is an FDA-approved mast cell stabilizer with an established clinical safety record in asthma, allergic rhinitis, and mastocytosis. PhenoNet's thesis is that re-engineering the molecule for pulmonary delivery — using a dry powder inhaler format with intellectual property covering drug, dosing, formulation, and delivery — can achieve brain and blood concentrations sufficient to engage three mechanistic pathways implicated in Alzheimer's disease: inhibition of amyloid-beta (Aβ) aggregation, suppression of pro-inflammatory cytokines and chemokines, and promotion of microglial phagocytosis of Aβ. The company is developing PHENOGENE-1A as a disease-modifying therapy intended to slow progression.
The Phase III trial, designated PHENOAD-002, is a randomized, double-blind, placebo-controlled study enrolling approximately 648 participants across roughly 90 sites in North America and Europe. A defining feature of the design is genotype stratification: participants are enrolled as both APOE4 carriers and non-carriers, with the primary endpoint assessed over 72 weeks. PhenoNet said the stratified design was informed by an exploratory observation of a numerical difference by APOE4 status in a prior Phase III trial, with non-APOE4 subgroup data cited as the primary support for advancing. First patient screening is expected in January 2027.
PhenoNet intends to pursue a Special Protocol Assessment (SPA) with the FDA to confirm that PHENOAD-002, if successful, could support a future 505(b)(2) new drug application — a regulatory pathway that permits reliance on existing safety data for the active ingredient, reflecting the established cromolyn safety record.
The competitive landscape for early Alzheimer's disease is now anchored by two approved anti-amyloid monoclonal antibodies. Eisai and Biogen's Leqembi Iqlik (lecanemab-irmb) received FDA approval for subcutaneous induction dosing in July 2026, complementing the earlier IV approval and the August 2025 subcutaneous maintenance approval. Eli Lilly's Kisunla (donanemab-azbt) received FDA approval in July 2024. Both agents require confirmed amyloid pathology for patient selection, carry mandatory APOE4 genotyping requirements due to elevated amyloid-related imaging abnormalities-edema (ARIA-E) risk in homozygous carriers, and require parenteral administration with ongoing MRI surveillance. PHENOGENE-1A's inhaled route and proposed non-amyloid-clearance mechanism offers differentiation from both.